Active Clinical Trials | LifeBridge Health

All Clinical Trials

Below is a list of all clinical trials, conducted by several of our specialty service lines. You may filter the list of trials by clicking the "Department" dropdown menu and selecting the area that you want to view or that pertains to you.

Clicking "Learn More" may either take you to more information about our departments that conduct the research, or to the official clinicaltrials.gov page for more information about the trial.

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)”

Study # S1827 Date Opened: 08/18/2023 (Khalert Only) Principal Investigator: David Perry, M.D.

Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Study # EA5221 Date Opened: 07/19/2024 Principal Investigator: Vishal Jindal, MD

Gynecologic Cancer

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Ca

Study # NRG GY026 Date Opened: 01/07/2023 (All Centers) Principal Investigator: Pallavi Kumar, M.D.

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (NCT#04267848)

Study # A081801 Date Opened: 08/17/2020 (All Centers) Principal Investigator: Qiwei Gai

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (NCT#3851445)

Study # LUNGMAP Date Opened: 04/09/2019 (All Centers) Principal Investigator: Qiwei Gai

Hematologic Cancer

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide(CC-92480), Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

Study # NCT05519085 Date Opened: 09/20/2022 Principal Investigator: Qiwei Gai

Supportive Cancers

Blinded Reference Set for Multicancer Early Detection Blood Tests

Study # A212102 Date Opened: 08/30/2022 (All Centers) Principal Investigator: Qiwei Gai

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Study # GS-US-595-6184 Date Opened: 12/12/2022 Principal Investigator: Wilfred Layne

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤

Study # NRG-BR009 Date Opened: 08/31/2023 (All Centers) Principal Investigator: Wilfred Layne

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Study # S2206 Date Opened: 11/27/2023 (Sinai & WKRCC) Principal Investigator: Qiwei Gai

Supportive Cancers

WF2304-A172401, Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

Study # NCT06418204 Date Opened: 01/30/2025 Principal Investigator: Pallavi Kumar, M.D.

NRG-LU008, Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

Study # NRG-LU008 Date Opened: 07/12/2023 Closing Date: 10/15/2031 Principal Investigator: David Perry, M.D. Sponsor: NRG Oncology

Brain, Breast Cancer, GI, GU, Melanoma, Lung Cancer

NRG-BN013, Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated SRS (FSRS) for Intact Brain Metastases

Study # NRG-BN013 Date Opened: 12/12/2024 Closing Date: 06/30/2028 Principal Investigator: David Perry, M.D. Sponsor: NRG Oncology

NRG-GI011: A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Study # NRG-GI011 Date Opened: 07/15/2025 Closing Date: 10/21/2030 Principal Investigator: David Perry, M.D. Sponsor: NRG Oncology

A012301: LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Study # A012301 Date Opened: 08/28/2025 Principal Investigator: Qiwei Gai Sponsor: Alliance

OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Study # A012103 Date Opened: 06/13/2023 Principal Investigator: Qiwei Gai

EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (Exact 2023-05 / NSABP B-64)

Study # 2023-05 Date Opened: 09/23/2025

NRG GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

Study # NRG GI008 Date Opened: 03/21/2023 (All Centers) Principal Investigator: Pallavi Kumar, M.D.